O
ITCI

OrbiMed’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

OrbiMed’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-163,000
Closed -$13.6M – 131
2024
Q4 		$13.6M Buy
+163,000
New +$13.4M 0.28% 66
2016
Q3 		– Sell
-885,400
Closed -$35.8M – 153
2016
Q2 		$34.4M Buy
885,400
+591,400
+201% +$21.3M 0.36% 61
2016
Q1 		$8.17M Buy
+294,000
New +$9.8M 0.09% 101

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

OrbiMed's ITCI Position: Q1 2025 in Review

OrbiMed sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 163,000 shares — an estimated $13.6M sold.

OrbiMed first reported a position in ITCI in Q1 2016 and held it in 3 quarters. The position peaked at $34.4M in Q2 2016. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • OrbiMed reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • OrbiMed sold 163,000 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $13.6M.
  • OrbiMed first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 3 quarters.
  • OrbiMed's Intra-Cellular Therapies Inc. position peaked at $34.4M in Q2 2016.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.